Article

Inflammation and Macular Oedema after Pars Plana Vitrectomy

Second University of Naples, Via Pansini 5, 80100 Napoli, Italy.
Mediators of Inflammation (Impact Factor: 3.24). 10/2013; 2013:971758. DOI: 10.1155/2013/971758
Source: PubMed

ABSTRACT

Cystoid macular oedema (CMO) is a major cause of reduced vision following intraocular surgery. Although the aetiology of CMO is not completely clarified, intraocular inflammation is known to play a major role in its development. The macula may develop cytotoxic oedema when the primary lesion and fluid accumulation occur in the parenchymatous cells (intracellular oedema) or vasogenic oedema when the primary defect occurs in the blood-retinal barrier and leads to extracellular fluid accumulation (extracellular oedema). We report on the mechanisms of CMO formation after pars plana vitrectomy and associated surgical procedures and discuss possible therapeutic approaches.

Download full-text

Full-text

Available from: Vito Romano
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose/Aim of study: We postulate that the timing of phacoemulsification relative to pars plana vitrectomy, internal limiting membrane peel (before, during or after) and gas is an important risk factor for cystoid macular edema. Materials and Methods: We report a retrospective study of 43 eyes in 43 patients. All patients underwent vitrectomy, internal limiting membrane peeling and gas for full-thickness macular hole. Patients were categorized according to their phakic status prior to vitrectomy. Group 1 remained phakic through the 12-month study and acted as a control group, group 2 had combined surgery, group 3 were pseudophakic prior to vitrectomy and group 4 became pseudophakic subsequent to vitrectomy. Patients with postoperative optical coherence tomography (OCT)-proven CME with at least one cyst within the OCT field associated with increased central macular thickness (CMT) were identified. Results: CME was noted in 6/43 patients (14%). CME occurred in 38% of group 4 compared to 0% of group 1, 11% of group 2 and 11% of group 3. This difference did not reach statistical significance when rates were compared to group 1 (Anova: group 2: p = 0.853; group 3: p = 0.876; group 4: p = 0.173). The mean (± standard deviation) LogMAR best-corrected mean visual acuity (BCVA) improved from 0.44 (±0.27) at time of CME diagnosis to 0.35 (±0.19), with a mean decrease in CMT from 392.2 (±102.5) µm to 287.7 (±34.0) µm. Conclusions: We report a trend of higher incidence and recurrence of CME in vitrectomized ILM-peeled eyes undergoing phacoemulsification than in other sequences of these procedures. - See more at: http://www.sciencedomain.org/abstract.php?iid=684&id=36&aid=6668#.VEn3AJN4pIc
    Full-text · Article · Jan 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The clinical efficacy of one or two intravitreal injections of a continued deliverance dexamethasone 700 μg implant in ten patients with persistent macular edema following uncomplicated phacoemulsification was evaluated. Complete ophthalmological examination and spectral domain optical coherence tomography were carried out. Follow-up was at day 7 and months 1, 2, 4, 6, 8, and 12. At baseline mean best corrected visual acuity was 62 Early Treatment Diabetic Retinopathy Study Chart letters, which showed statistically significant improvement at each follow-up, except at month 6, to reach 79 letters at month 12 ( P = 0.018 ). Prior to treatment mean central foveal thickness was 622 μm, which showed statistically significant improvement at each follow-up to reach a mean value of 282 μm ( P = 0.012 ) at month 12. Five patients received a second dexamethasone implant at month 7. Two patients were excluded from the study at months 4 and 8. Intraocular pressure remained stable during the study period with the exception of mild increase in two patients requiring topical therapy. In conclusion there was statistically significant improvement of best corrected visual acuity and mean central foveal thickness with one or two intravitreal dexamethasone implants over 12 months.
    Full-text · Article · Oct 2015